Kodiak’s Zenkuda Meets Phase 3 Goal in Wet AMD, With More Than Half of Patients on Six-Month Dosing

Zenkuda was non-inferior to Eylea in vision, dried fluid quickly, and put 54% of wet AMD patients on 24-week dosing under strict treat-to-dryness rules.